Bavarian Nordic on FDA special status: A huge validation

On Monday, the FDA awarded Danish biotech firm Bavarian Nordic a special regulatory status, which could cut down case processing of the firm’s RSV vaccine candidate. While a phase III trial is slated to begin soon, Bavarian still lags behind in the race to reach the potential billion-dollar RSV market. Still, there’s enough money to go around, says VP of communications, Rolf Sass Sørensen.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

It’s a feather in Bavarian Nordic’s cap to have been granted the especially sought-after special regulatory status for the company’s RSV vaccine candidate, dubbed MVA-BN RSV, from the US Food and Drug Administration (FDA) on Monday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading